of patient survival/response or progression-free survival. How successful Opdivo is as a treatment is also measured in clinical trials by looking at the number of patients who respond to the therapy with either complete or partial responses, which is known as the objective response rate (ORR) ...
However, there is no such period of stability requirement for other disease sites such as the liver, bone, or adrenal metastases, so why is this requirement necessary for brain metastases? Requiring time periods of CNS stability prior to inclusion on a trial may end up being a back-door way...